Compare AstraZeneca plc (AZN) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs RLX Technology Inc — how do they compare? AstraZeneca plc trades at $169.19 (market cap $253.13B), while RLX Technology Inc trades at $2.03 (market cap $2.42B). The key difference: AstraZeneca plc is far larger — about 104.6× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.05%). Which is the better fit depends on your goals.
| AZN | RLX | |
|---|---|---|
Market Cap | $253.13B | $2.42B |
Sector | Health | Technology |
52-Week High | $209.48 | $2.73 |
52-Week Low | $137.44 | $1.79 |
Enterprise Value | $279.37B | $1.05B |
Dividend Yield | 1.92% | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
RLX Technology trades at $1.97, up 1.03% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth driven by international expansion, though it missed EPS estimates for three consecutive quarters. RLX maintains strong profitability with a 22.47% net income margin and is debt-free with substantial cash flow from operations.
Outlook is mixed: strong fundamentals and industry growth potential are offset by recent earnings misses and a single analyst hold rating. Key risks include regulatory scrutiny in the vaping sector and execution challenges in global markets. The stock presents a value opportunity but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
